Influenza vaccination in patients with juvenile idiopathic arthritis under different treatments: safety and immune response

Table 3 Immunogenicity of H1N1, H3N2, and B influenza vaccine in JIA patients with or without anti-TNF therapy and healthy controls

	ADA + MTX therapy (n = 26)	MTX (n = 15) therapy	Healthy controls (n = 22)	p-values
A/Michigan (H1N1)
Seroprotection, no (%)
Baseline	15 (55.6%)	7 (46.7%)	11 (57.9%)	0.763
Second visit	22 (81.5%) *	15 (100%) *	17 (89.47%)*	0.155
Third visit	20 (74.1%)	14 (93.3%)	16 (84.2%)	0.138
Seroconversion rate	37%	73%	37%	0.102
GMT
Baseline	57.60	31.43	87.37	0.243
Second visit	141.40 *	317.14	229.47*	0.175
Third visit	111.20	327.14	167.47	0.093
A/Singapore (H3N2)
Seroprotection, no (%)
Baseline	9 (33.3%)	7 (46.7%)	7 (36.8%)	0.708
Second visit	24 (88.9%) *	12 (80.0%)	16 (84.2%)*	0.205
Third visit	16 (59.3%)	14 (93.3%)	16 (84.2%)	0.087
Seroconversion rate	52%	40%	37%	0.616
GMT
Baseline	24.40	46.43	46.31	0.705
Second visit	78.80 *	87.86*	80.26	0.820
Third visit	57.40	137.50	86.58	0.079
B/Maryland (B/Vic)
Seroprotection, no (%)
Baseline	1 (3.7%)	0 (0%)	1 (5.3%)	1.000
Second visit	4 (14.8%)	0 (0%)	4 (22.2%)	0.304
Third visit	4 (14.8%)	0 (0%)	2 (11.1%)	0.359
Seroconversion rate	7%	0%	11%	0.426
GMT
Baseline	5.60	7.50	9.74	0.633
Second visit	13.20	8.57	16.84	0.382
Third visit	10.80	13.57	20.26	0.398

ISSN: 1546-0096